Literature DB >> 2537243

Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation.

B Vandewalle1, J Lefebvre.   

Abstract

Catecholestrogens and especially 2-hydroxyestrone (2OH-E1) are estradiol metabolites locally formed in breast cancer cells. The present study demonstrates that the two parent compounds, estradiol (E2) and its metabolite 2OH-E1, exert opposite effects on hormone-sensitive breast cancer cell growth assessed by cell counts and transferrin receptor levels, and also on cell differentiation assessed by secreted proteins such as alpha-lactalbumin and gross cystic disease fluid protein (GCDFP-15). The present findings may highlight estradiol regulation in hormone-sensitive breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537243     DOI: 10.1016/0303-7207(89)90135-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  21 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

Review 2.  Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells.

Authors:  J B Adams
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

3.  Elevated expression of catechol-O-methyltransferase is associated with labor and increased prostaglandin E(2) production by human fetal membranes.

Authors:  Hassan Harirah; Chandrasekhar Thota; Melissa J Wentz; Wahiduz Zaman; Ayman Al-Hendy
Journal:  Am J Obstet Gynecol       Date:  2009-08-07       Impact factor: 8.661

Review 4.  Molecular genetics and racial disparities of uterine leiomyomas.

Authors:  Essam-Eldin R Othman; Ayman Al-Hendy
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2008-03-25       Impact factor: 5.237

5.  Circulating estrogen metabolites and risk of breast cancer in postmenopausal women.

Authors:  Alan A Arslan; Karen L Koenig; Per Lenner; Yelena Afanasyeva; Roy E Shore; Yu Chen; Eva Lundin; Paolo Toniolo; Göran Hallmans; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

6.  Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women.

Authors:  Vanessa W Lim; Jun Li; Yinhan Gong; Jian-Min Yuan; Tsung Sheng Wu; Geoffrey L Hammond; Aizhen Jin; Woon-Puay Koh; E L Yong
Journal:  Bone       Date:  2012-03-16       Impact factor: 4.398

Review 7.  Circulating sex steroids and breast cancer risk in premenopausal women.

Authors:  Susan E Hankinson; A Heather Eliassen
Journal:  Horm Cancer       Date:  2010-02-09       Impact factor: 3.869

8.  A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Authors:  Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson
Journal:  Breast Cancer Res Treat       Date:  2017-05-30       Impact factor: 4.872

9.  Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.

Authors:  A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

10.  Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women.

Authors:  A Heather Eliassen; Regina G Ziegler; Bernard Rosner; Timothy D Veenstra; John M Roman; Xia Xu; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.